CRVO Stock Summary and Trading Ideas (Cervomed | NASDAQ:CRVO)

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Cervomed trades on the NASDAQ stock market under the symbol CRVO.

As of March 6, 2026, CRVO stock price climbed to $4.11 with 44,019 million shares trading.

CRVO has a beta of -1.55, meaning it tends to be less sensitive to market movements. CRVO has a correlation of 0.03 to the broad based SPY ETF.

CRVO has a market cap of $38.03 million. This is considered a Sub-Micro Cap stock.

Last quarter Cervomed reported $322,569 in Revenue and -$.84 earnings per share. This fell short of revenue expectation by $-817,431 and missed earnings estimates by -$.23.

The top ETF exchange traded funds that CRVO belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

CRVO has outperformed the market in the last year with a return of +91.2%, while the SPY ETF gained +18.7%. However, in the most recent history, CRVO shares have underperformed the stock market with its stock returning -52.7% in the last 3 month period and -11.2% for the last 2 week period, while SPY has returned -1.7% and -2.5%, respectively.

CRVO support price is $3.70 and resistance is $4.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVO shares will trade within this expected range on the day.